Chlorendic acid supplier | CasNO.115-28-6

Name
Chlorendic acid
EINECS 204-078-9
CAS No. 115-28-6
Density 2 g/cm³
Solubility
Melting Point 239-242 °C
Formula C₉H₄Cl₆O₄
Boiling Point 471.7 °C at 760 mmHg
Molecular Weight 388.846
Flash Point 239.1 °C
Transport Information
Appearance solid
Safety 53-22-26-36/37/39-45
Risk Codes 40-41
Molecular Structure
Hazard Symbols Xi
Synonyms 5-Norbornene-2,3-dicarboxylicacid, 1,4,5,6,7,7-hexachloro- (6CI,8CI);1,4,5,6,7,7-Hexachloro-5-norbornene-2,3-dicarboxylicacid;1,4,5,6,7,7-Hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid;2H,3H-Hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylicacid;HET acid;Hexachloroendomethylenetetrahydrophthalicacid;NSC 22231;NSC 41876;
PSA 74.60000
LogP 3.23350

Synthetic route

: cadmium(II) nitrate tetrhydrate

: 115-28-6
Chlorendic acid

: 7732-18-5
water

: 68-12-2, 33513-42-7
N,N-dimethyl-formamide

: [Cd8(chlorendic acid(-2H))8(N,N-dimethylformamide)4(H2O)12]·8(N,N-dimethylformamide)

Conditions

Conditions	Yield
In water for 504h;	56%

...Expand

: 115-28-6
Chlorendic acid

: 107-19-7
propargyl alcohol

: 114646-85-4
Di-2-propinylchlorendat

Conditions

Conditions	Yield
With toluene-4-sulfonic acid Heating;

: 115-28-6
Chlorendic acid

: 2157-19-9
1,2,3,4,7,7-hexachloro-5,6-bis(hydroxymethyl)bicyclo<2.2.1>hept-2-ene

Conditions

Conditions	Yield
With lithium aluminium tetrahydride In diethyl ether Heating;

: 115-28-6
Chlorendic acid

: 56-35-9
bis(tri-n-butyltin)oxide

: (C4H9)3SnOOCC7H2Cl6COOH

Conditions

Conditions	Yield
In benzene byproducts: H2O; mole ratio of (C4H9)3SnOSn(C4H9)3 and carboxylic acid 1:2; at 20°C or at reflux temp. to remove of water formed by azeotropic distn.;

: 115-28-6
Chlorendic acid

: 74-86-2
acetylene

: 1,4,5,6,7,7-hexachloro-5-norbornene-2,3-dicarboxylic acid divinyl ester

Conditions

Conditions	Yield
decacarbonyldirhenium(0) In xylene at 160℃; under 15001.5 Torr; for 6h; Product distribution / selectivity;

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-[3-amino-2-(2-nitrophenyl)propionyl]-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-[3-amino-2-(2-nitrophenyl)propionyl]-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

: 115-28-6
Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-[3-amino-2-(2-nitrophenyl)propionyl]-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-[3-amino-2-(2-nitrophenyl)propionyl]-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions

Conditions	Yield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[(2-nitrophenyl)Gly]-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[(2-nitrophenyl)Gly]-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

: 115-28-6
Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[(2-nitrophenyl)Gly]-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[(2-nitrophenyl)Gly]-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions

Conditions	Yield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[3-amino-2-(2-nitrophenyl)propionyl]-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[3-amino-2-(2-nitrophenyl)propionyl]-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

: 115-28-6
Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[3-amino-2-(2-nitrophenyl)propionyl]-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-[3-amino-2-(2-nitrophenyl)propionyl]-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions

Conditions	Yield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-[(2-nitrophenyl)Gly]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-[(2-nitrophenyl)Gly]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

: 115-28-6
Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[(2-nitrophenyl)Gly]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[(2-nitrophenyl)Gly]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions

Conditions	Yield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

: 115-28-6
Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions

Conditions	Yield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

: 115-28-6
Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions

Conditions	Yield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-[4-[4-(1-aminoethyl)-2-methoxy-5-nitrophenoxy]butyryl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-[4-[4-(1-aminoethyl)-2-methoxy-5-nitrophenoxy]butyryl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

: 115-28-6
Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[4-[4-(1-aminoethyl)-2-methoxy-5-nitrophenoxy]butyryl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[4-[4-(1-aminoethyl)-2-methoxy-5-nitrophenoxy]butyryl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions

Conditions	Yield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

: 115-28-6
Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-(β-alanyl)-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions

Conditions	Yield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-Cys(t-Bu)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)- supported on NovaSyn TGR resin: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2,3-diaminopropionyl)-Cys(t-Bu)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-Glu(OtBu)-Glu(OtBu)-Ile-Glu(OtBu)- supported on NovaSyn TGR resin

: 115-28-6
Chlorendic acid

(4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S: (4-methoxy-3-nitrobenzoyl)-Glu(OtBu)-Glu(OtBu)-Glu(OtBu)-Ile-Phe-Gly-Glu(OtBu)-Phe-(2-amino-3-(1,4,5,6,7,7-hexachloro-bicyclo[2.2.1]hept-5-ene-3-(carboxylic acid)-2-carboxamido)propionyl)-(β-alanyl)-[3-amino-2-(2-nitrophenyl)propionyl]-(β-alanyl)-Tyr(PO(benzyloxy)OH)-[3-amino-2-(2-nitrophenyl)propionyl]-Glu(OtBu)-Ile-Glu(OtBu)-cystamine supported on Tentagel S

Conditions

Conditions	Yield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate solid phase reaction;

: C78H114N13O22PolS2

: 115-28-6
Chlorendic acid

: C87H116Cl6N13O25PolS2

Conditions

Conditions	Yield
With O‑(6‑chlorobezotriazol‑1‑yl)‑N,N,N,N‑tetramethyluronium hexafluorophosphate; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide solid phase reaction;

Chlorendic acid Chemical Properties

Product Name: Chlorendic acid (CAS NO.115-28-6)
IUPAC Name: 1,2,3,4,7,7-Hexachlorobicyclo[2.2.1]hept-2-ene-5,6-dicarboxylic acid

MF: C₉H₄Cl₆O₄
MW: 388.84
EINECS: 204-078-9
Mol File: 115-28-6.mol
MP: 239-242 °C(lit.)
Surface Tension: 77.2 dyne/cm
Density: 2 g/cm³
Flash Point: 239.1 °C
Enthalpy of Vaporization: 80.46 kJ/mol
Boiling Point: 471.7 °C at 760 mmHg
Vapour Pressure: 3.37E-10 mmHg at 25°C
Stability: Stable. Incompatible with strong oxidizing agents.
Product Categories: Organics; Alicyclic/Etch-Resistant Monomers; Lithography Monomers; Self Assembly&Contact Printing

Chlorendic acid Uses

Product Name: Chlorendic acid (CAS NO.115-28-6) is a variety of intermediate compounds.

Chlorendic acid Production

Product Categories:Organics;Alicyclic/Etch-Resistant Monomers;Lithography Monomers;Self Assembly&Contact Printing

Chlorendic acid Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
rat	LC	inhalation	> 790mg/m3/4H (790mg/m3)		National Technical Information Service. Vol. OTS0537100,
rat	LD	oral	> 1gm/kg (1000mg/kg)		National Technical Information Service. Vol. OTS0535786,

Chlorendic acid Safety Profile

Safety Information of Product Name: Chlorendic acid (CAS NO.115-28-6):
Hazard Codes: Xi
Risk Statements: 40-41
40:Limited evidence of a carcinogenic effect
41:Risk of serious damage to eyes
Safety Statements: 53-22-26-36/37/39-45
53:Avoid exposure - obtain special instruction before use
22:Do not breathe dust
26: When using 1,2,3,4,7,7-hexachlorobicyclo[2.2.1]hept-2-ene-5,6-dicarboxylic acid (115-28-6 ),in case of contact with eyes, rinse immediately with plenty of water and seek medical advice
36/37/39:Wear suitable protective clothing, gloves and eye/face protection
45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible)
WGK Germany: 3
RTECS : RB9000000

Chlorendic acid Specification

Chlorendic acid , its CAS NO. is 115-28-6, the synonyms are Chlorendic acid ; Labotest-bb lt00159272 ; het acid ; hexachloro-endo-methylenetetrahydrophthalic acid ; 1,4,5,6,7,7-hexachloro-5-norbornene-2,3-dicarboxylic acid ; 1,4,5,6,7,7-hexachlorobicyclo[2.2.1]-5-heptene-2,3-dicarboxylic acid ; 1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid ; 1,4,5,6,7,7-hexachloro-5-norbornene-2,3-dicarboxy .

Product Name

Chlorendic acid

Synthetic route

Chlorendic acid Chemical Properties

Chlorendic acid Uses

Chlorendic acid Production

Chlorendic acid Toxicity Data With Reference

Chlorendic acid Safety Profile

Chlorendic acid Specification

Related Products

Hot Products